|Articles|May 1, 2001
- Pharmaceutical Executive-05-01-2001
- Volume 0
- Issue 0
Friends of Complexity
Author(s)Wayne Koberstein
Pharmaceutical executives should study their own scientists. They construct clever tools to explore convoluted phenomena. They are the true friends of complexity.
Advertisement
Articles in this issue
over 24 years ago
Policy: Task Mastersover 24 years ago
Pharmacia's Carrie Cox: HBA Woman of the Yearover 24 years ago
Under Federal Fireover 24 years ago
Task Force: Enter the Fixersover 24 years ago
The Next Y2Kover 24 years ago
Political ScienceNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
